Is Vigil Neuroscience, Inc. (VIGL) a Buy, Sell, or Hold?
Vigil Neuroscience, Inc.
NASDAQ:VIGL
$2.47 USD
$0.17 (7.39%)
- Volume
- 336.25K
- Average Volume
- 118.73K
- Market Capitalization
- $100.97M
- P/E Ratio
- -1.21
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $6.06
- Year Low
- $2.08
- Payout Ratio
- $0.00
- Current Ratio
- $3.72
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VIGL |
| CUSIP | 92673K108 |
| CIK | 0001827087 |
| Web | https://www.vigilneuro.com |
| Phone | 857 254 4445 |
| Currency | USD |
| Employees | 64 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.72 |
| Quick Ratio | 3.72 |
| Cash Ratio | 1.47 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 52.21 |
| Cash Flow | -1.20 |
| Price / Cash Flow | -2.08 |
| Price / Book | 1.13 |
Price Target and Rating
| Average Stock Price Forecast | $11.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -77.55% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.13 |
| Trailing P/E Ratio | -1.21 |
| PEG Ratio | -0.43 |
| P/E Growth | -0.43 |
| Net Income | $-82.64M |
| Net Margin | -4270.89% |
| Pretax Margin | -4270.89% |
| Return on Equity | -83.89% |
| Return on Assets | -62.92% |
Financials Score
| AltmanZ Score | -3.05 |
| Piotroski Score | 2.00 |
| Working Capital | 83.14M |
| Total Assets | 131.27M |
| Ebit | -88.43M |
| Market Cap | 100.97M |
| Total Liabilities | 42.72M |
Poll Results
About Vigil Neuroscience, Inc. (NASDAQ:VIGL) Stock
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is ... headquartered in Cambridge, Massachusetts.
2024-10-09 11:58:00
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
2024-09-17 07:00:00
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company.
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
2024-09-16 16:05:00
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
Vigil Neuroscience to Present at Upcoming September Investor Conferences
2024-08-29 07:00:00
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
2024-08-23 11:47:00
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Frequently Asked Questions
-
What is the current Vigil Neuroscience, Inc. (VIGL) stock price?
-
Vigil Neuroscience, Inc.(NASDAQ:VIGL) stock price is $2.47 in the last trading session. During the trading session, VIGL stock reached the peak price of $6.06 while $2.08 was the lowest point it dropped to. The percentage change in VIGL stock occurred in the recent session was 7.39% while the dollar amount for the price change in VIGL stock was $0.17.
-
VIGL's industry and sector of operation?
-
The NASDAQ listed VIGL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VIGL?
-
Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations
Ms. Jennifer Ziolkowski CPA | Chief Financial Officer
Eric Brophy | Senior Manager of Information Technology
Christian Mirescu Ph.D. | Senior Vice President & Head of Neuroimmunology
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director -
How many employees does VIGL have?
-
Number of VIGL employees currently stands at 64. VIGL operates from 1 Broadway, Cambridge, MA 02142, US.
-
Link for VIGL official website?
-
Official Website of VIGL is: https://www.vigilneuro.com
-
How do I contact VIGL?
-
VIGL could be contacted at phone #857 254 4445 and can also be accessed through its website. VIGL operates from 1 Broadway, Cambridge, MA 02142, US.
-
How many shares of VIGL are traded daily?
-
The average number of VIGL shares traded daily for last 3 months was 118.73K.
-
What is the market cap of VIGL currently?
-
The market value of VIGL currently stands at $100.97M with its latest stock price at $2.47